momelotinib
Sign in to saveMomelotinib, sold under the brand name Ojjaara among others, is an anticancer medication used for the treatment of myelofibrosis. It is a Janus kinase inhibitor and it is taken by mouth.
Chemical data
- Formula
- C23H22N6O2
- Molecular weight
- 414.5 g/mol
- IUPAC name
- N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
via PubChem
Research
252 papers- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
- Momelotinib.2006
- Momelotinib.2012
- Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.Lancet (London, England) · 2023
- Momelotinib for the treatment of myelofibrosis.
Article
7 sectionsContents
- Medical uses
- Pharmacology
- Pharmacodynamics
- Society and culture
- Legal status
- References
- External links
{{Chembox | ImageFile = Momelotinib.svg | ImageClass = skin-invert-image | ImageSize = 255 | PIN = N-(Cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide | OtherNames =
| Section1 =
Connections
Categories
4-Morpholinyl compoundsAminopyrimidinesBenzamidesChembox image size setChemical articles with multiple CAS registry numbersChemical articles with multiple compound IDsChemical articles without CAS registry numberChemical pages without ChemSpiderIDChemical pages without DrugBank identifierChemicals using indexlabelsDrugs developed by GSK plc